Innate Pharma (IPHA) Consolidated Net Income (2019 - 2025)

Innate Pharma has reported Consolidated Net Income for 7 years, with the latest figure at -$24.2 million in Q2 2025.

• For the quarter ending Q2 2025, Consolidated Net Income rose 9.4% year-over-year to -$24.2 million; the trailing twelve-month figure through Dec 2025 stood at -$103.7 million (down 23.88% YoY), and the FY2022 full-year result was -$132632.2, up 98.42% from the prior year.
• Consolidated Net Income for Q2 2025 stood at -$24.2 million, up from -$52.9 million in the prior quarter.
• The five-year high for Consolidated Net Income was $7.5 million in Q2 2021, with the low at -$52.9 million in Q4 2024.
• Historically, Consolidated Net Income has averaged -$12.1 million across 5 years, with a median of -$8.1 million in 2023.
• The largest YoY upside for Consolidated Net Income was 5203.87% in 2023 against a maximum downside of 6093965.51% in 2023.
• Innate Pharma's Consolidated Net Income stood at -$8.4 million in 2021, then surged by 100.0% to -$133.65 in 2022, then tumbled by 6093965.51% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then jumped by 54.3% to -$24.2 million in 2025.
• The last three Consolidated Net Income figures came in at -$24.2 million (Q2 2025), -$52.9 million (Q4 2024), and -$26.7 million (Q2 2024), per Business Quant data.